Immunology Seminar Series, Seppo Meri
May 18th at 14:00
Virtual event
Seppo Meri, University of Helsinki: Role of complement in pregnancy disorders
Host: Riitta Lahesmaa ( rilahes@utu.fi )
Register latest May 17th at: https://link.webropolsurveys.com/S/0B9738AEBC03A3C1
Zoom link and iCalendar invitation to join the online event will be sent to all registered participants one day before the event.
Registration to this event closes May 17th at 12:00.
Immunology seminar series is jointly organised by Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience.
For further information contact Anne Lahdenperä ( ankahy@utu.fi ) or Riitta Lahesmaa ( rilahes@utu.fi ), University of Turku
Seppo Meri, MD, PhD, is Professor of Immunology at the Medical Faculty, University of Helsinki, Finland, and the Chief Physician of Research in Microbiology at HUSLAB, laboratory of the Helsinki University Hospital. He is also a visiting professor at the Humanitas University, Milan, Italy. His medical specialty is in Clinical Microbiology.
Professor Meri served as a postdoctoral fellow at the University of Texas in 1988 and in 1989–90 as an EMBO fellow at MRC, Cambridge, UK. His research interests include diseases related to disturbances in complement regulation and reasons for increased susceptibility to microbial infections. He has published ≈ 270 original research articles and 130 reviews or textbook chapters on complement, autoimmunity and microbial escape of immunity.
He has been the President of the Scandinavian Society for Immunology 2001-2007 and of the European Complement Network 2001-2003. He served as the Secretary General of the International Union of Immunological Societies 2010-2016 and as a member of the FEBS Publication Committee 2014-2018. He is a Member of the Finnish Academy of Science and Letters since 2009.
Selected publications:
Reichhardt MP, Lundin K, Lokki AI, Recher G, Vuoristo S, Katayama S, Tapanainen JS, Kere J, Meri S*, Tuuri T*. Complement in human pre-implantation embryos: Attack and defense. Front Immunol. 10:2234, 2019. doi: 10.3389/fimmu.2019.02234
Teirilä L, Heikkinen-Eloranta J, Kotimaa J, Meri S, Lokki AI. Regulation of the complement system and immunological tolerance in pregnancy. Semin Immunol. 45:101337, 2019. doi: 10.1016/j.smim.2019.101337
Kaartinen K, Martola L, Aaltonen S, Meri S. Diagnostic Dilemma of Thrombotic Microangiopathy in Pregnancy. Kidney Int Rep. 6:529-533, 2020. doi: 10.1016/j.ekir.2020.10.036
Lokki AI, Teirilä L, Triebwasser M, Daly E, Bhattacharjee A, Uotila L, Llort Asens M, Kurki MI, Perola M, Auro K, Salmon JE, Daly M, Atkinson JP, Laivuori H, Fagerholm S, Meri S; Finnpec. Dysfunction of complement receptors CR3 (CD11b/18) and CR4 (CD11c/18) in pre-eclampsia: a genetic and functional study. BJOG. Feb 4, 2021. doi: 10.1111/1471-0528.16660
Recent Posts
- Early-career researchers invited to BioCity Pre-Symposium on 26 August. Registration is now open!Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026